Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “

A number of other equities analysts have also commented on BLCM. Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. ValuEngine lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 11th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price target (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. BidaskClub lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $26.20.

Bellicum Pharmaceuticals (NASDAQ:BLCM) traded down 1.18% during midday trading on Tuesday, hitting $10.05. 347,347 shares of the stock traded hands. The company has a 50-day moving average price of $11.03 and a 200-day moving average price of $11.37. The firm’s market cap is $333.92 million. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the firm earned ($0.61) earnings per share. Analysts predict that Bellicum Pharmaceuticals will post ($3.02) EPS for the current year.

WARNING: “Zacks Investment Research Upgrades Bellicum Pharmaceuticals, Inc. (BLCM) to “Hold”” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/24/zacks-investment-research-upgrades-bellicum-pharmaceuticals-inc-blcm-to-hold.html.

A number of hedge funds have recently made changes to their positions in the stock. Sphera Funds Management LTD. boosted its stake in Bellicum Pharmaceuticals by 25.0% during the second quarter. Sphera Funds Management LTD. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,920,000 after buying an additional 50,000 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Bellicum Pharmaceuticals during the second quarter worth $728,000. Goldman Sachs Group Inc. boosted its stake in Bellicum Pharmaceuticals by 48.1% during the first quarter. Goldman Sachs Group Inc. now owns 42,664 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 13,863 shares in the last quarter. Numeric Investors LLC acquired a new stake in Bellicum Pharmaceuticals during the second quarter worth $1,137,000. Finally, Vanguard Group Inc. boosted its stake in Bellicum Pharmaceuticals by 17.8% during the first quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock worth $13,100,000 after buying an additional 160,151 shares in the last quarter. 55.91% of the stock is currently owned by institutional investors and hedge funds.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.